Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Moderna reported a quarterly loss of $2.11 per share, better than the Zacks Consensus Estimate of a loss of $2.6, and an improvement from a loss of $2.5 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $678 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.81%, although this represents a decline from year-ago revenues of $966 million [2] - Moderna has outperformed the S&P 500, with shares increasing by about 36% since the beginning of the year, while the S&P 500 has declined by 0.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$2.14 on revenues of $254.87 million, and for the current fiscal year, it is -$6.70 on revenues of $2.09 billion [7] - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]